SCHEMBL24968899

SCHEMBL24968899

COC(=O)CCOCCc1cccc(C#N)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.46
FFAR4 Q5NUL3 1/20 0.46
MEP1A Q16819 1/20 0.46
MEP1B Q16820 1/20 0.46
GLA P06280 1/20 0.44
CNR1 P21554 1/20 0.44
RAB9A P51151 1/20 0.43
GAA P10253 1/20 0.42
VNN1 O95497 3/20 0.42
LMNA P02545 1/20 0.41
GSK3B P49841 1/20 0.40
MAPK8 P45983 1/20 0.40
ERCC1 P07992 1/20 0.40
ERCC4 Q92889 1/20 0.40
SCN8A Q9UQD0 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
ROCK2 O75116 1/20 0.39
ROCK1 Q13464 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3926844 0.88 FFAR1 (0.54) FFAR1FFAR4MEP1AMEP1BGLA
SCHEMBL12258715 0.86 FFAR1 (0.48) FFAR1FFAR4MEP1AMEP1BGLA
SCHEMBL1247027 0.86 FFAR1 (0.44) FFAR1FFAR4MEP1AMEP1BGLA
SCHEMBL1246091 0.85 FFAR1 (0.59) FFAR1FFAR4MEP1AMEP1BGLA
SCHEMBL29165966 0.84 FFAR1 (0.48) FFAR1FFAR4MEP1AMEP1BGLA
SCHEMBL2662070 0.79 ERCC1 (0.52) FFAR1FFAR4MEP1AMEP1BGLA
SCHEMBL16672747 0.78 CA12 (0.55) FFAR1RAB9ALMNACYP11B1CYP11B2
SCHEMBL2772477 0.78 FFAR1 (0.53) FFAR1FFAR4MEP1AMEP1BGLA
SCHEMBL24637999 0.77 GLA (0.49) FFAR1FFAR4GLACNR1GAA
SCHEMBL926321 0.77 SMN1; SMN2 (0.47) GAAVNN1SMN1; SMN2EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240351997-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) 2024-10-24 US disclosed
EP-4378938-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2024-06-05 EP disclosed
WO-2023006013-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240351997-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF PARP6, PARP4, PARP3 FFAR1 3723/4885FFAR4 3973/4885MEP1A 3323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.